DXCM Stock Recent News
DXCM LATEST HEADLINES
DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Five Health and Fitness stocks to buy now are: SFM, DXCM, HIMS, UNFI, GDRX.
DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins, leading me to lower my rating from buy to hold. Despite demographic tailwinds and a growing market, gross margin declines and cost pressures present significant downside risks. My updated DCF analysis yields a price target of $92.90 for DXCM stock, only a 9% upside from current prices, reducing the margin of safety.
DexCom, Inc. NASDAQ: DXCM has once again demonstrated its formidable position in the continuous glucose monitoring (CGM) market, delivering outstanding first-quarter 2025 financial results that underscore its sustained momentum. The company's performance, driven by strong product demand, successful innovation, and strategic market access expansion, strongly supports an ambitious trajectory for the remainder of 2025, indicating a clear path towards further solidifying its leadership in diabetes technology.
The S&P 500 is enjoying its longest winning streak since 2004. We have highlighted the five best stocks in the S&P 500 over the past month.
I initially rated DexCom's stock as sell due to competition and GLP-1 threats, but surprising 1Q25 growth prompts an upgrade to hold. DXCM posted better than expected growth figures in 1Q25, establishing a reaccelerating trend in growth for the company. However, DXCM's competitor product, Abbott's Libre Freestyle, has been growing faster despite larger sales.
DXCM's first-quarter 2025 earnings decline despite increasing sales. Its performance in 2025 is expected to be fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets.
Nasdaq jumps as Dexcom, Palantir, and ON Semi soar. Jobs report beats forecasts, easing inflation fears and driving US stock market optimism.
Dexcom, the maker of glucose monitors for patients with diabetes, reports a strong first quarter.
Marketwide challenges, like those created by President Donald Trump's tariff policies, cause many investors to shift their focus to the short term -- leading to panic-selling and a spiraling stock market. While it's a perfectly human reaction to volatility, it's a tendency investors should avoid.